BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 11556747)

  • 1. Mitosin and DNA topoisomerase IIalpha: two novel proliferation markers in the prognostication of diffuse astrocytoma patient survival.
    Korkolopoulou P; Patsouris E; Konstantinidou AE; Christodoulou P; Thomas-Tsagli E; Kouzelis K; Angelidakis D; Rologis D; Davaris P
    Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):207-14. PubMed ID: 11556747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas.
    Konstantinidou AE; Korkolopoulou P; Kavantzas N; Mahera H; Thymara I; Kotsiakis X; Perdiki M; Patsouris E; Davaris P
    Histol Histopathol; 2003 Jan; 18(1):67-74. PubMed ID: 12507285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerase IIα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
    Winther TL; Torp SH
    PLoS One; 2017; 12(3):e0172316. PubMed ID: 28301542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
    Faria MH; Gonçalves BP; do Patrocínio RM; de Moraes-Filho MO; Rabenhorst SH
    Neuropathology; 2006 Dec; 26(6):519-27. PubMed ID: 17203587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas.
    Taniguchi K; Wakabayashi T; Yoshida T; Mizuno M; Yoshikawa K; Kikuchi A; Nakashima N; Yoshida J
    J Neurosurg; 1999 Sep; 91(3):477-82. PubMed ID: 10470824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas--an immunohistochemical study.
    Habberstad AH; Gulati S; Torp SH
    Diagn Pathol; 2011 May; 6():43. PubMed ID: 21609421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
    Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
    Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival.
    Zhao H; Yu H; Liu Y; Wang Y; Cai W
    Clin Neuropathol; 2008; 27(2):83-90. PubMed ID: 18402387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase IIalpha expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome.
    Schrader C; Meusers P; Brittinger G; Teymoortash A; Siebmann JU; Janssen D; Parwaresch R; Tiemann M
    Leukemia; 2004 Jul; 18(7):1200-6. PubMed ID: 15116121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival.
    Park SH; Suh YL
    Histopathology; 2003 Apr; 42(4):395-402. PubMed ID: 12653952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA topoisomerase IIalpha expression in optic pathway gliomas of childhood.
    Bredel M; Slavc I; Birner P; Czech T; Haberler C; Ströbel T; Wolfsberger S; Budka H; Hainfellner JA
    Eur J Cancer; 2002 Feb; 38(3):393-400. PubMed ID: 11818205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA topoisomerase IIalpha protein and mRNA expression in intracranial meningiomas.
    Kunishio K; Morisaki K; Matsumoto Y; Nagao S
    Brain Tumor Pathol; 2000; 17(3):105-10. PubMed ID: 11310917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA topoisomerase IIalpha expression correlates with cell proliferation but not with recurrence in intracranial meningiomas.
    Konstantinidou AE; Patsouris E; Korkolopoulou P; Kavantzas N; Mahera H; Davaris P
    Histopathology; 2001 Oct; 39(4):402-8. PubMed ID: 11683942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
    Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
    Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma.
    Provencio M; Corbacho C; Salas C; Millan I; Espana P; Bonilla F; Ramon Cajal S
    Clin Cancer Res; 2003 Apr; 9(4):1406-11. PubMed ID: 12684412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of DNA topoisomerase I, IIalpha, and IIbeta in human brain tumors.
    Morisaki K; Kuroda S; Matsumoto Y; Kunishio K; Nagao S
    Brain Tumor Pathol; 2000; 17(1):7-13. PubMed ID: 10982004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.